Author of

• 30943

  +

  P2.04 - Immuno-oncology (ID 167)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Immuno-oncology
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30982

    +

    P2.04-34 - FCGR2B Expression as a Regulator of Immunity in Non-Small Cell Lung Cancer Patients (Now Available) (ID 458)

    10:15 - 18:15  |  Author(s): Ying-Yin Chen
    • Abstract
    • Slides

    Background
    

    FCGR2B (CD32B), a receptor on the B cell membrane, induces the production of inhibitory messages to maintain the homeostasis of the immune system and prevent excessive activation of B cells to attack their own antigens. Therefore, FCGR2B may cause immune cells to not effectively search and kill for cancer cells.This study examined the level of FCGR2B expression on B cells associated with immunity in non-small cell lung cancer (NSCLC) patients.

    Method
    

    Healthy volunteers and lung cancer patients were recruited. All control donors’ and patients’ peripheral blood were collected. 200ul blood with appropriate amount of antibody was incubated for 10-15 min at room temperature in the dark and then lysed with 1ml VersaLyse Lysing Solution for 10-15 min at room temperature in the dark. Resuspend in 1ml PBS+ 1% fix solution then were counted by cytoflex flow cytometer (Beckman Coulter). For surface marker analysis, B cells were collected assessing the levels of CD19, CD32, CD21, CD24, CD27, CD38, and IgM/IgD by flow cytometric assay. T cells subtypes including CD3, CD4, CD8, CD27, CD28, CD45, CD45RA, CD57, CCR7 and PD1 were counted by cytoflex flow cytometer.

    Result
    

    In this study, healthy volunteers (n=9 ) were compared with NSCLC patients (n=17) to detect the expression of FCGR2B on B cell. We found that Class Switched Memory Cell in NSCLC patients had lower performance than healthy subjects (NSCLC patients v.s. healthy subjects: 65.10 ± 15.72 v.s. 70.76 ± 7.26, p = 0.013). Class Switched Memory Cell was significant lower in advanced stage than that in early stage NSCLC patients (advanced stage v.s. early stage: 54.68 ± 27.21 v.s. 77.73 ± 7.12, p = 0.044). The expression of FCGR2B (CD19CD32) in NSCLC patients was slightly lower than that in healthy subjects (NSCLC patients v.s. healthy subjects: 19.68 ± 10.07 v.s. 32.98 ± 23.92, p = 0.099), but did not reach statistically significant differences. The expression of FCGR2B (CD19CD32) was significantly positively correlated with CD4 Naïve T cell ( R = 0.789; B = 0.291; p < 0.001) and CD3CD4CD45RA (R = 0.765; B = 0.301; p = 0.001).

    

    Conclusion
    

    NSCLC patients with reduced numbers of Class Switched Memory B Cell are more prone to progress lung cancer disease. The positive correlation between FCGR2 B cells and naive T cells in blood is also observed. Future studies focusing on the presence of these B cell subtypes, antigen specificity and interaction with T cells are necessary to further elucidate in NSCLC patients.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.